Core Insights - Fresenius Medical Care (FME) emphasizes data-driven insights and real-world evidence to enhance patient care and improve outcomes for individuals with kidney disease globally [1][2] - The company presents 52 abstracts at the 62nd Congress of the European Renal Association (ERA), focusing on critical areas of nephrology, including home care, critical care, and hemodiafiltration [2][4] Research Highlights - Key presentations include studies on intradialytic arterial oxygen saturation instability, health status in hemodiafiltration versus hemodialysis, and the impact of fluid overload on hospitalization risk [4][5] - The CONVINCE trial analysis links hemodiafiltration to slower health decline and improved quality of life in dialysis patients [4][5] Innovations and Collaborations - FME introduces a novel AI-based recipe recommendation system for dialysis patients, enhancing nutritional management [5] - The company aims to optimize treatment durations in hemodialysis to improve survival outcomes, reinforcing treatment time as a modifiable factor [5] Company Overview - Fresenius Medical Care serves approximately 4.2 million patients worldwide, with around 299,000 patients receiving dialysis treatments through its network of 3,675 clinics [4][6] - The company is a leading provider of dialysis products and is listed on both the Frankfurt Stock Exchange and the New York Stock Exchange [6]